NCT03521830View on ClinicalTrials.gov

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

57

Participants

Timeline

Start Date

November 27, 2018

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions

Basal Cell Carcinoma

Interventions

DRUG

Nivolumab

480mg IV every 4 weeks

DRUG

Ipilimumab

1mg/kg IV every 4 weeks for 4 doses

DRUG

Relatlimab

480 mg IV q4wks

Trial Locations (1)

21231

RECRUITING

Johns Hopkins Hospital, Baltimore

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03521830 - Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma | Biotech Hunter | Biotech Hunter